Abstract
Bacterial expression of β‐lactamases, which hydrolyze β‐lactam antibiotics, contributes to the growing threat of antibacterial drug resistance. Metallo‐β‐lactamases, such as NDM‐1, use catalytic zinc ions in their active sites and hydrolyze nearly all clinically available β‐lactam antibiotics. Inhibitors of metallo‐β‐lactamases are urgently needed to overcome this resistance mechanism. Zinc‐binding compounds are promising leads for inhibitor development, as many NDM‐1 inhibitors contain zinc‐binding pharmacophores. Here, we evaluated 13 chelating agents containing benzimidazole and benzoxazole scaffolds as NDM‐1 inhibitors. Six of the compounds showed potent inhibitory activity with IC50 values as low as 0.38 μM, and several compounds restored the meropenem susceptibility of NDM‐1‐expressing E. coli. Spectroscopic and docking studies suggest ternary complex formation as the mechanism of inhibition, making these compounds promising for development as NDM‐1 inhibitors.
Funding Information
  • Duke University
  • National Institutes of Health

This publication has 44 references indexed in Scilit: